VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
FORA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
FORAForian Inc.
$2.17$68M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. FORA
  4. Financial Ratios

Forian Inc. (FORA) Financial Ratios

Latest Ratios: P/E Ratio -23.5x · EV/EBITDA N/A · ROE -9.6%. (2019–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

FORA Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Market Cap$68M$66M$64M$94M$87M$287M——
Enterprise Value$55M$53M$66M$111M$110M$293M——
P/E Ratio →-23.48——8.14————
P/S Ratio2.242.183.184.615.3316.98——
P/B Ratio2.272.212.133.417.0411.39——
P/FCF23.4922.85226.31144.55————
P/OCF23.4922.85226.31129.57————

P/E links to full P/E history page with 30-year chart

FORA EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
EV / Revenue—1.753.285.446.7117.36——
EV / EBITDA————————
EV / EBIT———41.97————
EV / FCF—18.38233.84170.50————

FORA Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Gross Margin52.5%52.5%63.6%73.3%69.2%72.1%93.0%—
Operating Margin-8.2%-8.2%-34.7%-27.3%-115.4%-163.6%-914.7%—
Net Profit Margin-9.5%-9.5%-18.7%54.2%-158.2%-157.3%-914.0%—

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
ROE-9.6%-9.6%-13.1%55.3%-138.2%-145.7%-90.7%—
ROA-6.3%-6.3%-7.0%20.7%-50.4%-76.5%-78.2%-719.8%
ROIC-7.5%-7.5%-13.6%-10.5%-42.6%-98.1%-71.2%—
ROCE-8.2%-8.2%-16.5%-12.2%-43.1%-90.1%-90.7%—

FORA Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Debt / Equity0.000.000.220.832.051.00——
Debt / EBITDA————————
Net Debt / Equity—-0.430.070.611.830.26-0.06—
Net Debt / EBITDA————————
Debt / FCF—-4.477.5325.96————
Interest Coverage-17.34-17.34-4.233.18-21.65-81.29——

Net cash position: cash ($13M) exceeds total debt ($12137)

FORA Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Current Ratio2.972.972.688.563.225.299.720.38
Quick Ratio2.972.972.688.563.225.149.720.38
Cash Ratio2.202.202.117.092.424.579.450.33
Asset Turnover—0.690.430.340.350.300.04—
Inventory Turnover—————4.63——
Days Sales Outstanding—97.50118.78160.3390.3064.97147.17—

FORA Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Dividend Yield————————
Payout Ratio————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Earnings Yield———12.3%————
FCF Yield4.3%4.4%0.4%0.7%————
Buyback Yield0.6%0.6%0.5%3.7%0.0%0.0%——
Total Shareholder Yield0.6%0.6%0.5%3.7%0.0%0.0%——
Shares Outstanding—$31M$31M$32M$32M$32M$30M$30M

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetHealthy
Cash FlowBurning
Top Statement Risk

High Revenue Volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Market Valuation Reflects Growth Uncertainty

Based on recent financial data, Forian trades at a price-to-sales ratio of 2.24, which appears to discount the company's potential as a healthcare data provider while simultaneously pricing in the significant volatility and regulatory risks inherent in its cannabis-exposed software and services business model.

The negative P/E ratio of -23.48 underscores the company's current inability to generate consistent bottom-line earnings, forcing investors to rely on revenue-based multiples. This valuation suggests that the market remains skeptical of the company's transition toward high-margin life sciences data, preferring to treat the stock as a speculative play on cannabis infrastructure.

Capital Efficiency Remains Under Pressure

As reported in quarterly filings, Forian's ROIC has deteriorated to -34.3% in 2026Q1, indicating that the company is currently destroying shareholder value rather than compounding it, a trend that warrants further investigation into the efficacy of their recent capital allocation and data infrastructure investments.

The sharp decline in return on invested capital suggests that the costs associated with maintaining and expanding the data lake are not yet yielding commensurate returns. Investors should monitor whether this is a temporary byproduct of aggressive R&D spending or a structural issue where the underlying business model fails to achieve the necessary scale to generate positive returns.

Working Capital Cycles Signal Inefficiency

According to recent SEC filings, Forian's asset turnover has remained stagnant at 0.17 in 2026Q1, while DSO has fluctuated significantly, suggesting that the company faces challenges in converting its service-based revenue into cash efficiently compared to more mature healthcare information services peers.

The high DSO figures, which reached 151 in early 2024, imply that the company may be struggling with collections from its smaller cannabis-retail client base. This inefficiency in working capital management likely contributes to the erratic cash flow profile and necessitates a higher liquidity buffer than would otherwise be required.

Liquidity Buffer Masks Operational Burn

Based on reported figures, Forian maintains a current ratio of 3.14, which appears to provide a robust short-term cushion, yet this liquidity is largely a function of recent cash accumulation rather than the operational self-sufficiency typically expected of a mature software-as-a-service provider.

While the current ratio suggests the company is well-positioned to meet its short-term obligations, the lack of consistent operating cash flow means this liquidity is finite. Investors should monitor the burn rate closely, as the current cash position may be depleted if the company cannot achieve operating profitability before the next phase of infrastructure investment.

Misapplication of SaaS Valuation Metrics

The most commonly misapplied metric for Forian is the standard SaaS-based P/S multiple, which obscures the fact that a significant portion of revenue is derived from lumpy, project-based government contracts rather than recurring, high-margin software subscriptions that typically command premium valuations in the market.

Applying a pure-play SaaS multiple to Forian ignores the high cost of revenue associated with data acquisition and the volatility of its government-contract segment. Analysts should instead focus on the quality of recurring revenue and the contribution margin of the life sciences data segment to better assess the company's true long-term earning potential.

Download Financial Ratios Data

Includes 30+ ratios · 7 years · Updated daily

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

FORA — Frequently Asked Questions

Quick answers to the most common questions about buying FORA stock.

What is Forian Inc.'s P/E ratio?

Forian Inc.'s current P/E ratio is -23.5x. The historical average is 8.1x.

What is Forian Inc.'s ROE?

Forian Inc.'s return on equity (ROE) is -9.6%. The historical average is -57.0%.

Is FORA stock overvalued?

Based on historical data, Forian Inc. is trading at a P/E of -23.5x. Compare with industry peers and growth rates for a complete picture.

What are Forian Inc.'s profit margins?

Forian Inc. has 52.5% gross margin and -8.2% operating margin.